{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:13:11Z","timestamp":1779279191335,"version":"3.51.4"},"reference-count":53,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,9,10]]},"abstract":"<jats:p> Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The cells are characterized as CD20<jats:sup>+<\/jats:sup> CD5<jats:sup>+<\/jats:sup> CD23<jats:sup>\u2212<\/jats:sup> with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. Response to chemotherapy usually results in a tumor response but unmaintained remissions are short and the median survival is 3 to 4 years. The treatment approach to newly diagnosed patients with MCL depends on the patient's eligibility for stem cell transplantation (SCT). Those who are eligible are usually treated with either rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by SCT or rituximab-HyperCVAD (cyclophosphamide, vincristine, doxorubicin, decadron, cytarabine, and methotrexate) followed by observation. The purine nucleoside analogues also have activity as single agents and with rituximab. Unfortunately none of these approaches can definitively cure patients with MCL, and new agents are needed. Recent studies in patients with relapsed MCL have shown substantial antitumor activity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rituximab. Studies integrating these novel agents earlier in the disease course or in combination with each other will hopefully produce more durable responses with less toxicity. <\/jats:p>","DOI":"10.1200\/jco.2005.55.017","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T04:07:52Z","timestamp":1126238872000},"page":"6409-6414","source":"Crossref","is-referenced-by-count":118,"title":["Current Treatment Approaches for Mantle-Cell Lymphoma"],"prefix":"10.1200","volume":"23","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"BIB1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00366-5"},{"key":"BIB2","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-199811000-00011"},{"key":"BIB3","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.3.319"},{"key":"BIB4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04761.x"},{"key":"BIB5","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008242729509"},{"key":"BIB6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20923"},{"key":"BIB7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02303.x"},{"key":"BIB8","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290016890"},{"key":"BIB9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11934"},{"key":"BIB10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3907"},{"key":"BIB11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3999"},{"key":"BIB12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2730"},{"key":"BIB13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.11.3889"},{"key":"BIB14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00684.x"},{"key":"BIB15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096"},{"key":"BIB16","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"BIB17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"BIB18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"BIB19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401121"},{"key":"BIB20","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723331"},{"key":"BIB21","doi-asserted-by":"publisher","DOI":"10.1080\/10428190127511"},{"key":"BIB22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"BIB23","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998-1932,"},{"key":"BIB24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"BIB25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"BIB26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"BIB27","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al: Rituximab plus hyperCVAD (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M\/A) in untreated mantle cell lymphoma (MCL): Prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS). Blood 104: 2004 (abstr 128)","DOI":"10.1182\/blood.V104.11.128.128"},{"key":"BIB28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.579"},{"key":"BIB29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.546"},{"key":"BIB30","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"BIB31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"BIB32","unstructured":"Inwards D, Brown D, Fonseca R, et al: NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity. Blood 94:660a,1999,  (suppl 1)"},{"key":"BIB33","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00143-0"},{"key":"BIB34","unstructured":"Inwards DJ, Fonseca R, Kurtin PJ, et al: NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as therapy for previously treated mantle cell lymphoma: Promising single agent activity limited by brief response duration. Blood 96:140a,2000,"},{"key":"BIB35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"BIB36","doi-asserted-by":"crossref","unstructured":"Oki Y, Pro B, Delpassand E, et al: A phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 104: 2004 (abstr 2632)","DOI":"10.1182\/blood.V104.11.2632.2632"},{"key":"BIB36A","unstructured":"Zelenetz AD, Donnelly G, Halaas J, et al: Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab\/iodine I131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate. Blood 102: 2003 (abstr 1477)"},{"key":"BIB37","doi-asserted-by":"crossref","unstructured":"Nachbaur D, Greinix HT, Koller E, et al: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-\/intermediate-grade B non-Hodgkin's lymphoma (NHL): A report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol 23:23,2005,","DOI":"10.1007\/s00277-004-1003-3"},{"key":"BIB38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.09.007"},{"key":"BIB39","unstructured":"Lefrere F, Delmer A, Levy V, et al: Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica 89:1275,2004-1276,"},{"key":"BIB40","doi-asserted-by":"crossref","unstructured":"Popplewell LL, Nademanee A, Carter N, et al: Autologous vs allogeneic cell transplantation for mantle cell lymphoma (MCL): Outcomes over a 10-year period at City of Hope. Blood 104: 2004 (abstr 894)","DOI":"10.1182\/blood.V104.11.894.894"},{"key":"BIB41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh069"},{"key":"BIB42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"},{"key":"BIB43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"BIB44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"BIB45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"BIB46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"BIB47","unstructured":"Winter JN, Inwards D, Erwin W, et al: Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: Early outcome results. Blood 100:411a,2002,  (abstr 1597)"},{"key":"BIB48","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.559"},{"key":"BIB49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"BIB50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"BIB51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"BIB52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.55.017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:13:29Z","timestamp":1653513209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.55.017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,10]]},"references-count":53,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2005,9,10]]}},"alternative-id":["10.1200\/JCO.2005.55.017"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.55.017","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,10]]}}}